Special Issue "Mucins and Cancers"
Deadline for manuscript submissions: closed (25 November 2023) | Viewed by 7855
Interests: cancer; autoimmunity; mental health; vaccines; exercise; infectious diseases; drugs; healthy aging; bioactives
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Cancer Vaccines: Research and Applications
Special Issue in Vaccines: Therapeutic Approaches for Type 1 and Type 2 Diabetes
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series I
Special Issue in Vaccines: Multiple Sclerosis and Its Complications: Clinical Trials
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series II
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases
Special Issue in Biologics: Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines
Special Issue in Vaccines: Multiple Sclerosis, Complications and Therapeutics 2.0
Special Issue in Molecules: Advances in Research of Short Peptides II
Special Issue in Biologics: Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes
Special Issue in Cancers: Checkpoint Markers and Cancer Microenvironment: What Do We Know?
Special Issue in International Journal of Molecular Sciences: Chronic Diseases: Gut-Brain-Immune-Microbiome Axis
Special Issue in International Journal of Molecular Sciences: Mechanisms and Interventions for Neurological and Psychological Disorders
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases 2.0
Special Issue in Biomedicines: Bioactive Compounds in Chronic Diseases
Special Issue in International Journal of Molecular Sciences: Mechanisms and Interventions for Neurological and Psychological Disorders 2.0
Special Issue in Biologics: Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines: Part II
Special Issue in Viruses: SARS-CoV-2: Vaccine Design and Host Immunity
Topics: Inflammation: The Cause of All Diseases
Topics: Recent Advances in Healthy Ageing
Topics: Inflammation: The Cause of all Diseases 2.0
From the late 1980s to the early 1990s, mucins were identified to play a key role on cancer cells. The first mucin to be identified was human MUC1 expressed on epithelial cells and overexpressed on adenocarcinomas. By the mid-1990s, human clinical trials were conducted in cancer patients with the aim of targeting immune responses to MUC1. Soon after, other mucins were identified, such as MUC2, MUC3, MUC4, MUC5, MUC6, and MUC21. The aberrant expression of some of these mucins—including MUC1, MUC4, MUC13, and MUC16—are also associated with diverse human malignancies. Mucins are also associated with the diagnosis, metastatic progression, prognosis outcomes, inflammation, function, therapy, and development of drugs and vaccines. In this Special Issue, we celebrate over 30 years of mucins in research, especially studies that have shown links between mucins and cancer. I invite you to submit an article to this Special Issue. We look forward to receiving your contributions.
Prof. Dr. Vasso Apostolopoulos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug development
- cancer therapy
- cancer prognosis